Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis
- Subrata Ghosh
- , Brian G. Feagan
- , Elyssa Ott
- , Christopher Gasink
- , Bridget Godwin
- , Colleen Marano
- , Ye Miao
- , Tony Ma
- , Edward V. Loftus
- , William J. Sandborn
- , Silvio Danese
- , Maria T. Abreu
- , Bruce E. Sands
- Western University
- LLC
- Merck
- Intercept Pharmaceuticals
- Johnson & Johnson
- Mayo Clinic Rochester, MN
- University of California at San Diego
- Mirador Therapeutics
- Vita-Salute San Raffaele University
- University of Miami
- Icahn School of Medicine at Mount Sinai
Research output: Contribution to journal › Article › peer-review